1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Mental Health Market Trends
Market Access Impact: Parkinson’s Disease (US) 2017

Market Access Impact: Parkinson’s Disease (US) 2017

  • July 2017
  • ID: 5175256
  • Format: PDF
  • By Firstword Pharma

Summary

Table of Contents


Are high cost and market access problems costing your brand market share?

Are market barriers holding your brand back? According to our survey of US-based neurologists, 8 of the 11 Parkinson’s disease treatments we asked them about are losing market share because of barriers. High cost and market access problems are the main culprits, but understanding the unique combination of barriers and competitive dynamics your brand faces is critical if you want to take back enough share to move ahead of rivals.

Learn how 7 barriers affect your market share, see who you take share from, and who gets your lost share in Market Access Impact: Parkinson’s Disease (US).

Based on a survey of 100 US-based neurologists, the report covers 11 major therapies from Abbvie, GlaxoSmithKline, Impax Pharmaceuticals, Novartis, Teva, UCB, US Worldmeds, and Valeant.


Top Takeaways

Most brands lose share: Barriers affect a quarter of all prescriptions, and all but 3 of the surveyed brands see a net market share loss because of them.
Market access is the #1 challenge: Market access barriers affect more prescriptions than any others.
Many brands are too expensive: 30%-50% of surveyed doctors can’t prescribe 7 of the surveyed brands due to cost.
One brand is having trouble getting onto formularies: More than 40% of doctors can’t prescribe this brand because it’s not included.
Another brand has a huge perception problem: Nearly half of surveyed doctors would not consider prescribing it.
Eliminating barriers would shake up the market: 5 brands would climb by 1 or 2 places each, and 2 of them would close in on the second-place brand.

Insight into 11 Major Parkinson’s disease Drugs

Apokyn (apomorphine; US Worldmeds)
Azilect (rasagiline; Teva)
Comtan (entacapone; Novartis)
Duopa (levodopa/carbidopa intraduodenal; Abbvie)
Neupro (rotigotine; UCB)
Requip (ropinirole; GlaxoSmithKline)
Requip XL (ropinirole ER; GlaxoSmithKline)
Rytary (levodopa/carbidopa; Impax Pharmaceuticals)
Stalevo (levodopa/carbidopa/entacapone; Novartis)
Tasmar (tolcapone; Valeant)
Xadago (safinamide; US Worldmeds)


Exploring Market Access Barriers

Market Access Impact: Parkinson’s Disease (US) explores key issues affecting drug manufacturers. You’ll learn:

How barriers affect market access:

What brands do doctors prescribe the most?
How many prescriptions do barriers affect?
Which barriers have the biggest impact?


How barriers affect your brand:

How many doctors prescribe your brand? How many don’t, but would consider it?
Why don’t doctors prescribe your brand? What do they prescribe instead?
Which competing brands does your brand take market share from?

A Report Based on Expert Knowledge

We surveyed 100 US-based neurologists, chosen from the largest community of validated physicians in the world.


All respondents have:
Been practicing for 2+ years
Prescribed at least one of the listed products
Seen at least 5 patients with Parkinson’s disease in the last month

We conducted the survey between June 1st and 7th, 2017. 














Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Veronica helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Metabotropic Glutamate Receptor 4 - Pipeline Review, H2 2019

Metabotropic Glutamate Receptor 4 - Pipeline Review, H2 2019

  • $ 3500
  • August 2019

Metabotropic Glutamate Receptor 4 - Pipeline Review, H2 2019SummaryMetabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Metabotropic glutamate receptor 4 is a protein encoded by the GRM4 gene. ...

Alpha Synuclein - Pipeline Review, H2 2019

Alpha Synuclein - Pipeline Review, H2 2019

  • $ 3500
  • August 2019

Alpha Synuclein - Pipeline Review, H2 2019SummaryAlpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Alpha-synuclein is a protein normally found ...

Cognitive Impairment Associated With Schizophrenia - Pipeline Review, H2 2019

Cognitive Impairment Associated With Schizophrenia - Pipeline Review, H2 2019

  • $ 2000
  • September 2019

Cognitive Impairment Associated With Schizophrenia - Pipeline Review, H2 2019SummaryThe latest Pharmaceutical and Healthcare disease pipeline guide Cognitive Impairment Associated With Schizophrenia - ...


ref:plp2017

Reportlinker.com © Copyright 2019. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on